These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11385890)

  • 1. Systemic treatment of metastatic breast cancer.
    Johnston SR
    Hosp Med; 2001 May; 62(5):289-95. PubMed ID: 11385890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upstaging tamoxifen? New classes of drugs emerging for breast cancer.
    Twombly R
    J Natl Cancer Inst; 2002 Apr; 94(7):474-5. PubMed ID: 11929942
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of metastatic breast carcinoma].
    Puglisi F; Sobrero A
    Ann Ital Chir; 1999; 70(3):377-89. PubMed ID: 10466241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer].
    Longo F; Mansueto G
    Tumori; 2004; 90(6):1-12. PubMed ID: 15762372
    [No Abstract]   [Full Text] [Related]  

  • 6. [The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
    Porpiglia M; Genta F; Vicelli R; De Nicola B; Ferraris F; Piccinno R; Benedetto C
    Minerva Ginecol; 2002 Apr; 54(2):115-31. PubMed ID: 12032450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiestrogen therapy in the treatment of breast neoplasms].
    Alba E; Ragonesi G; Colla F; Mazzoleni A; Farina C
    Minerva Ginecol; 2002 Jun; 54(3):245-51. PubMed ID: 12063440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
    Wu K; Brown P
    J Natl Cancer Inst; 2003 Jun; 95(11):766-7. PubMed ID: 12783921
    [No Abstract]   [Full Text] [Related]  

  • 11. Hormone- and chemotherapy-induced bone loss in breast cancer.
    Coleman RE
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):16-20. PubMed ID: 15202583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retardation of progression of bone metastasis in mammary carcinoma patients by intravenous pamidronate treatment: results of a randomized, controlled, multinational study].
    Adamietz IA
    Strahlenther Onkol; 1998 Aug; 174(8):438. PubMed ID: 9739387
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
    Goss PE; Strasser K
    Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
    Fabian CJ; Kimler BF
    Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New aromatase inhibitors in the treatment of advanced breast cancer.
    Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
    Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting.
    Morales L; Neven P; Paridaens R
    Curr Opin Oncol; 2005 Nov; 17(6):559-65. PubMed ID: 16224233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.